Pfizer’s RSV Vaccine Has Potential To Protect High-Risk Adults

A new study says Pfizer’s RSV vaccine has the potential to protect high-risk adults ages 18 to 59 from the disease.

A press release explains that respiratory syncytial virus, or RSV, could be prevented or lessened in those who have been vaccinated with ABRYSVO. A Phase 3 clinical trial evaluated the differences in administering a single dose of the vaccine versus a placebo in adults up to age 59 who are at risk for the virus.

In Pfizer’s study, 681 adults ages 18 to 59 with chronic conditions received a single dose of ABRYSVO or a placebo. A second study enrolled approximately 200 immunocompromised adults — around half were 60 or older — who received two doses of ABRYSVO one month apart.

The study found that 9.5% of adults in this age group have a chronic condition that puts them at risk for RSV. In the age bracket of 50-64, that percentage more than doubles to 24.3%. The study also tested the safety of the drug in adults with increased risk for RSV who have asthma, diabetes, and chronic obstructive pulmonary disease.

“These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., senior vice president and head of vaccine research and development at Pfizer. Anderson noted that they are “excited” to address this significant vaccine need.

ABRYSVO is a vaccine designed to protect against RSV. It has the potential to become the first and only RSV vaccine for adults 18 years and older, pending regulatory approval.

RSV is a contagious virus and a common cause of respiratory illness. The virus can affect the lungs and breathing passages of an infected individual and can potentially cause severe illness in young infants, older adults, and individuals with certain chronic medical conditions. RSV infections typically cause 60,000 to 160,000 hospitalizations and 6,000 to 13,000 deaths each year.